DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Pivot X, Gligorov J, Müller V et al.
Patientsʼ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.
Ann Oncol 2014;
25: 1979-1987
We do not assume any responsibility for the contents of the web pages of other providers.